China Biologic Products Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From China Biologic Products Holdings, Inc.
Lilly To Decide Next Steps After Formal FDA 'Nay' For First Chinese PD-1
The official verdict is in for sintilimab and the results are not surprising. But some view the setback for "Made In China" innovation as a chance to reflect and move forward.
Balancing Act: Orphan Drug Makers Slash Prices In China As New Mechanism Allures
From Biogen to Takeda, multinationals have been cutting prices in China in a bid to seize the emerging market for rare disease treatments, as Beijing strives to expand market access.
Rare Chance Or Passing Opportunity: China Expands Orphan Drug Coverage With Steep Price Cuts
Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.
APAC Life Sciences Valuation Trends: Chinese Firms Eclipse Japan, India Peers
Chinese healthcare and life sciences firms now overshadow their peers in Japan and India in terms of key valuation metrics amid COVID-19 and China has also witnessed significant M&A activity at high revenue multiples.
- Large Molecule
- Other Names / Subsidiaries
- CBPO Holdings Limited
- CBPO Group Limited
- Guiyang Dalin Biologic Technologies Co., Ltd.
- Guizhou Taibang Biological Products Co. Ltd.
- Shandong Taibang Biological Products Co., Ltd.
- Tianxinfu Medical Appliance Co., Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.